EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities

Roxana Liana Lucaciu iD, Adriana Corina Hangan iD, Luminița Simona Oprean, Lucia Maria Procopciuc iD

International Journal of Molecular Sciences · 26.09.2026 · 27 (19) · 8619

DOI: 10.3390/ijms27198619 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.09.2026. Verfasst von Roxana Liana Lucaciu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, "Iuliu-Hațieganu" University of Medicine and Pharmacy, 400349…. Hauptthemen laut MEDLINE: Breast Neoplasms, Histone Deacetylase Inhibitors, Histone Deacetylases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most frequently diagnosed malignancy in women, and hormone receptor-positive disease represents its predominant subtype. Aromatase inhibitors (AIs) are a cornerstone of endocrine therapy, particularly in postmenopausal patients, but their long-term efficacy is frequently limited by intrinsic or acquired resistance. Increasing evidence indicates that epigenetic dysregulation, especially aberrant histone deacetylase (HDAC) activity, contributes to altered estrogen receptor signaling, transcriptional plasticity, activation of compensatory survival pathways, and endocrine treatment failure. This narrative review examines the biological and therapeutic interplay between aromatase and HDACs in breast cancer, integrating evidence from mechanistic studies, in vitro models, preclinical experiments, and clinical trials. HDAC inhibition may restore endocrine sensitivity by modifying chromatin accessibility, reactivating estrogen-responsive and tumor-suppressor genes, suppressing adaptive pathways such as HER2, NF-κB, and PI3K/AKT/mTOR signaling, and promoting cell-cycle arrest and apoptosis. Preclinical studies support synergistic or sensitizing effects of combined AI–HDAC inhibition, while clinical trials with entinostat, tucidinostat, panobinostat, and exemestane- or letrozole-based regimens have produced heterogeneous results. These findings suggest that endocrine–epigenetic combinations may benefit selected patients rather than represent an universally effective strategy. Future clinical translation will require improved HDAC selectivity, optimized dosing, toxicity management, and validation of predictive biomarkers enabling biomarker-guided patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHistone Deacetylase InhibitorsHistone DeacetylasesDrug Resistance, NeoplasmAromatase InhibitorsAromataseHumansFemaleAnimalsReceptors, EstrogenEpigenesis, GeneticSignal Transduction

Stichwörter der Autor:innen

HDAC inhibitorsaromatase inhibitorsbreast cancerestrogen receptor-positive breast cancer

Substanzen

Histone Deacetylase InhibitorsHistone DeacetylasesAromatase InhibitorsAromataseReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Pharmaceutical Biochemistry and Clinical Laboratory, Faculty of Pharmacy, "Iuliu-Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
  • Department of Inorganic Chemistry, Faculty of Pharmacy, "Iuliu-Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Department of Medical Biochemistry, Faculty of Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.

ORCID-Profile: Roxana Liana Lucaciu, Adriana Corina Hangan, Lucia Maria Procopciuc

Zitieren

APA

Lucaciu, R. L., Hangan, A. C., Oprean, L. S., & Procopciuc, L. M. (2026). Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities. International Journal of Molecular Sciences, 27(19), 8619. https://doi.org/10.3390/ijms27198619

Vancouver

Lucaciu RL, Hangan AC, Oprean LS, Procopciuc LM. Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities. International Journal of Molecular Sciences. 2026;27(19):8619. doi:10.3390/ijms27198619

BibTeX
@article{Lucaciu2026,
  author = {Lucaciu, Roxana Liana and Hangan, Adriana Corina and Oprean, Luminița Simona and Procopciuc, Lucia Maria},
  title = {Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {19},
  pages = {8619},
  doi = {10.3390/ijms27198619}
}
Kostenlos starten →